November 29, 2022

Rosuvastatin is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken by mouth.

Resuvostatin sold under the trade name crestor among others is a stand medication used to prevent cardiovascular disease in those at high risk and treat abnormal lipids it is recommended to be used together with dietary changes exercise and weight loss it is taken by mouth common side effects include abdominal pain nausea headaches and muscle pains serious

Side effects may include rhabdomyolysis liver problems and diabetes used during pregnancy may harm the baby like all saturn’s prosubastatin works by inhibiting hmg co-reductase an enzyme found in the liver that plays a role in producing cholesterol risuvastatin was patented in 1991 and approved for medical use in the united states in 2003. it is available as

A generic medication medical uses the primary use of rasubostatinous for prevention of cardiovascular disease and those at high risk in the treatment of abnormal lipids effects on cholesterol levels the effects of rasuvostatin on low density lipoprotein ldl cholesterol or dose related higher doses were more efficacious in improving the lipid profile of patients

With hypercholesterolemia than milligram equivalent doses of atorvastatin and milligram equivalent or higher doses of simvastatin and pravastatin meta-analysis showed that rosuvastatin is able to modestly increase levels of high-density density lipoprotein hdl cholesterol as well as with other satins a 2014 cochrane review determined there was good evidence for

Resuvostatin lowering non-hdl levels linearly with dose hdl increases by seven percent with no dose effect noted rosuvastatin has multiple contraindications conditions that warrant withholding treatment with rosuvastatin including hypersensitivity to resubostatin or any component of the formulation active liver disease elevation of serum transaminases pregnancy

Or breastfeeding resubastadin must not be taken while pregnant as it can cause serious harm to the baby in the case of breastfeeding it is unknown whether rosuvastatin is passed through breast milk but due to the potential of disrupting the infant’s lipid metabolism patients should not breastfeed while on rasubistadine the risk of myopathy may be increased in

Asian americans because asians appear to process the drug differently half the standard dose can have the same cholesterol-lowering benefit in those patients though a full dose could increase the risk of side effects a study by the drugs manufacturer astrazeneca indicated therefore the lowest dose is recommended in asians myopathy as with all saturns there is a

Concern of rhabdomyolysis a severe undesired side effect the u.s food and drug administration fda has indicated that it does not appear that the risk of rhabdomyolysis is greater with prestor than with other marketed saturns but has mandated that a warning about this side effect as well as a kidney toxicity warning be added to the product label diabetes mellitus

Saturn’s increased the risk of diabetes consistent with fda’s review which reported a 27 percent increase in investigator reported diabetes mellitus and rosuvastatin treated people structure rasubastatin has structural similarities with most other synthetic satins example of torvastatin ceravastatin and patavastatin but unlike other satins for subastadine contains

Sulfur in sulfonyl functional group prestor is actually a calcium salt of resubastatin that is for superstatin calcium in which calcium replaces the hydrogen in the carboxylic acid group on the right of the skeletal formula at the top right of this page mechanism of action resubostatin is a competitive inhibitor of the enzyme hmg coa reductase having a mechanism

Of action similar to that of other saturns punitive beneficial effects of rasubostatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme q10 levels in patients with chronic heart failure pharmacodynamics in a cochrane systematic review the dose-related magnitude of rosuvastatin on

Blood lipids was determined over the dose range of 1 to 80 milligrams per day strong linear dose-related effects were found total cholesterol was reduced by 22.1 to 44.8 percent ldl cholesterol by 31.2 to 61.2 percent non-hdl cholesterol by 28.9 to 56.7 and triglycerides by 14.4 to 26.6 pharmacokinetics absolute bioavailability of resuvastatin is about 20 and

C-max is reached in three to five hours administration with food did not affect the auc according to the original sponsor submitted clinical study and as per product label however a subsequent clinical study has shown a marked reduction in resume statin exposure when administered with food it is 88 protein bound mainly dal human fraction absorbed of rosuvastatin

Is frequently misquoted in the literature is approximately 0.5 50 due to a miscalculated hepatic extraction ratio in the original submission package subsequently corrected by the fda reviewer it is likely that closer to 0.25 25 of the administered dose is absorbed rosuvastatin is metabolized mainly by cyp2c9 and not extensively metabolized approximately 10

Percent is recovered as metabolite endes methyl resubastatin it is excreted in feces 90 primarily and the elimination half-life is approximately 19 hours patent protection and generic versions the main patent protecting rosuvastatin 337 314 due to expire in 2016 was challenged as being an improper reissue of an earlier patent this challenge was rejected in

2010 confirming protection until 2016. in april 2016 the fda approved the first generic version of rosuvastatin from watson pharmaceuticals inc in july 2016 myelin gained approval for its generic resubostatin calcium debate and criticisms in october 2003 several months after its introduction in europe richard horton the editor of the medical journal the lancet

Criticized the way crestor had been introduced astrazeneca’s tactics in marketing its cholesterol-lowering drug presuvastatin raised disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines according to his editorial the lancet’s editorial position is that the data for

Crester’s superiority rely too much on extrapolation from the lipid profile data surrogate end points and too little on hard clinical endpoints which are available for other saturn’s that had been on the market longer the manufacturer responded by stating that few drugs had been tested so successfully on so many patients in correspondence published in the

Lancet astrazeneca’s ceo sir tom mckillip called the editorial plot and incorrect and slammed the journal for making such an outrageous critique of a serious well-studied medicine in 2004 the consumer interest organization public citizen filed a citizen’s petition with the fda asking that crest orbee withdrawn from the u.s market on the 11th of march 2005 the

Fda issued a letter to sydney m wolff md of public citizen both denying the petition and providing an extensive detailed analysis of findings that demonstrated no basis for concerns about resumes dating compared with the other saturns approved for marketing in the united states

Transcribed from video
Rosuvastatin By quick learner’s point